Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Director Declaration

4 Sep 2009 11:57

RNS Number : 5578Y
Celsis International PLC
04 September 2009
 



CELSIS INTERNATIONAL PLC

("Celsis", "the Company" or "the Group")

Directors' Declaration

4 September 2009: Celsis International plc, the life sciences products and laboratory services company, today announces that following the appointment of Christopher Mills and Jeremy Brade as directors of the Company as announced on 3 September 2009, the Company confirms the following information about these directors.

 

Christopher Mills 

Current directorships of publicly quoted companies:
 
Castle Support Services Plc (formerly Castle Acquisitions Plc)
Catalyst Media Group Plc
Essenden Plc
Inspired Gaming Group Plc
M J Gleeson Plc
Nationwide Accident Repair Services Plc
North Atlantic Smaller Companies Investment Trust Plc
Prime Focus London Plc
Oryx International Growth Fund Ltd
 
 

Directorships of publicly quoted companies held within last five years:
 
Aberdeen Park Investments Plc
Albany Capital Plc
American Opportunity Trust Plc 
Izodia Plc 
Jarvis Porter Group Plc 
Jubilee Investment Trust Plc
Langley Park Investment Trust Plc
Lonrho Plc
Mid-States Plc
Nationwide Security Group Plc
Second London American Trust Plc
Tinopolis Plc (formerly Acquisitor Plc)
 

 

 

Mr Mills is a director of Izodia Plc, which entered into a company voluntary liquidation on 19 May 2004. All creditors have now been paid in full and the voluntary arrangement was completed on 20 January 2009.

Receivers were appointed to Versatile Group Limited, and its subsidiaries Versatile Projects Limited and Castle Finance Limited, of which Mr Mills was a director by Bank of Scotland who had charges and cross guarantees supporting a debt of £2.04 million in addition to which the group had net liabilities in excess of £700,000 to unpaid creditors. Versatile Group Limited was dissolved under section 652 of the Companies Act 1985 on 15 May 2001.

Receivers were appointed to Nationwide Security Group Limited, of which Mr Mills was a director, on 16 February 2000 and realised sufficient assets to repay all creditors and make a small distribution.

Administrators were appointed to PNC Telecom Plc on 23 June 2003 and the administration order was discharged (and PNC Telecom Plc resumed business) on 15 June 2004. Mr Mills was a director of PNC Telecom Plc until his resignation on 3 February 2003.

Jarvis Porter Group Plc was put into administration in August 2007 and all creditors have been paid.

There are no further details to be disclosed under the Continuing Obligations provisions of the Listing Rules (new rules LR9.6.13) in respect of Mr Mills

 

Jeremy Brade 

Current directorships of publicly quoted companies:

None

Directorships of publicly quoted companies held within last five years:

Nationwide Accident Repair Services Plc 

Administrators were appointed to PNC Telecom Plc on 23 June 2003 and the administration order was discharged (and PNC Telecom Plc resumed business) on 15 June 2004. Mr Brade was a director of PNC Telecom Plc from 3 February 2003 until 23 June 2003.

United Industries Public Limited Company went into Administration on 5 April 2006.  Mr Brade had resigned as a director on 28 October 2005.

There are no further details to be disclosed under the Continuing Obligations provisions of the Listing Rules (new rules LR9.6.13) in respect of Mr Brade. 

Further information can be found on its website at www.celsis.com.

Enquiries:

Celsis International plc

Tel: 01223 598 428

Jay LeCoque

Robyn LaLonde

Nomura Code Securities

Tel: 020 7776 1200

Chris Collins

Phil Walker

Financial Dynamics

Tel: 020 7831 3113

Jonathan Birt

Susan Quigley

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNLIMMTMMAMBIL
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.